Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Trying to think positive

I seem to remember that the very first version of this request was rejected on some technicality deeming it inconsistent with the requirements of the request submittal at that time (I cannot remember the exact nature of the rejection). The request was subsequently resubmitted, but not until after the NIRC was released, as I remember it.

My understanding is that if the request for reexamination is received after the NIRC then the request must address the amended version of the patent, which is the most current at that moment. My understanding comes from a reading of the USPTO rules posted here on this forum about 4 months or so ago. If, as you state, the request refers to the pre-amended claims, this would seem in conflict with my understanding, presuming that my understanding is valid.

Corrections welcomed.

Cheers,

DG

Share
New Message
Please login to post a reply